Dose finding study of PSC833, a novel MDR reversing agent, with daunorubicin and ARA-C in untreated elderly patients with acute myeloid leukaemia (AML).

被引：0
|
作者：
Sonneveld, P
Lowenberg, B
Vossebeld, P
Malkhandi, J
Covelli, A
Dekker, AW
Ossenkoppele, G
Milligan, D
Verhoef, G
Ferrant, A
Yin, J
Gratwohl, A
Kovacsovics, T
Burnett, A
机构：
[1] UNIV ROTTERDAM HOSP,ROTTERDAM,NETHERLANDS
[2] VRIJE UNIV AMSTERDAM,AZ,AMSTERDAM,NETHERLANDS
[3] UNIV UTRECHT,AZ,UTRECHT,NETHERLANDS
[4] BIRMINGHAM HEARTLANDS HOSP,BIRMINGHAM B9 5ST,W MIDLANDS,ENGLAND
[5] MANCHESTER ROYAL INFIRM,MANCHESTER M13 9WL,LANCS,ENGLAND
[6] UZ GASTHUISBERG,LOUVAIN,BELGIUM
[7] UZ ST LUC,BRUSSELS,BELGIUM
[8] CHU VAUDOIS,KANTONSSPITAL BASEL,LAUSANNE,SWITZERLAND
[9] NOVARTIS PHARMA AG,BASEL,SWITZERLAND
来源：
BLOOD | 1997年 / 90卷 / 10期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2517 / 2517
页数：1
相关论文
共 50 条
  • [1] A phase I dose-finding study of PSC 833, a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine (PSC-MEC) in poor prognosis acute leukemia (AML).
    Visani, G
    Milligan, D
    Leoni, F
    Chang, J
    Kelsey, S
    Marcus, R
    Powles, R
    Schey, S
    Covelli, A
    [J]. BLOOD, 1997, 90 (10) : 2518 - 2518
  • [2] The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis
    van der Holt, B
    Löwenberg, B
    Burnett, AK
    Knauf, WU
    Shepherd, J
    Piccaluga, PP
    Ossenkoppele, GJ
    Verhoef, GEG
    Ferrant, A
    Crump, M
    Selleslag, D
    Theobald, M
    Fey, MF
    Vellenga, E
    Dugan, M
    Sonneveld, P
    [J]. BLOOD, 2005, 106 (08) : 2646 - 2654
  • [3] Dose escalation studies of ara-c (A), daunorubicin (D) and etoposide (E) with and without multidrug resistance (MDR) modulation with PSC-833 (P) in untreated adults with acute myeloid leukemia (AML) < 60 years:: Final induction results of CALGB 9621.
    Kolitz, JE
    George, SL
    Dodge, RK
    Hoke, E
    Hurd, DD
    Powell, BL
    Velez-Garcia, E
    Caligiuri, MA
    Moore, JO
    Vardiman, JW
    Bloomfield, CD
    Larson, RA
    [J]. BLOOD, 2001, 98 (11) : 461A - 461A
  • [4] Daunorubicin and cytarabine compared with daunorubicin, cytarabine and the MDR1 reversal agent PSC-833 in elderly patients with acute myelogenous leukemia.
    van der Holt, B
    Sonneveld, P
    Burnett, AK
    Vossebeld, PJM
    Beverloo, B
    Rosenkranz, G
    Dugan, M
    van Putten, WLJ
    Wheatley, K
    Lowenberg, B
    [J]. BLOOD, 2004, 104 (11) : 246A - 246A
  • [5] A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia
    A K Burnett
    N H Russell
    R K Hills
    J Kell
    O J Nielsen
    M Dennis
    P Cahalin
    C Pocock
    S Ali
    S Burns
    S Freeman
    D Milligan
    R E Clark
    [J]. Leukemia, 2017, 31 : 310 - 317
  • [6] A comparison of clofarabine with ara-C, each in combination with daunorubicin as induction treatment in older patients with acute myeloid leukaemia
    Burnett, A. K.
    Russell, N. H.
    Hills, R. K.
    Kell, J.
    Nielsen, O. J.
    Dennis, M.
    Cahalin, P.
    Pocock, C.
    Ali, S.
    Burns, S.
    Freeman, S.
    Milligan, D.
    Clark, R. E.
    [J]. LEUKEMIA, 2017, 31 (02) : 310 - 317
  • [7] DAE (DAUNORUBICIN, ARA-C, AND ETOPOSIDE) AND INTERMEDIATE DOSE ARA-C FOR REMISSION INDUCTION AND CONSOLIDATION TREATMENT OF ADULT PATIENTS WITH ACUTE MYELOID-LEUKEMIA
    HWANG, WL
    YOUNG, JH
    GAU, JP
    HU, HT
    TSAI, YT
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 1992, 15 (06): : 531 - 534
  • [8] A phase I study of induction chemotherapy for older patients (pts) with acute myeloid leukemia (AML) using ara-C (A), daunorubicin (D) and etoposide (E) with and without the MDR modulator PSC-833 (P): Cancer and leukemia group B (CALGB) study 9420.
    Lee, E
    George, S
    Caligiuri, M
    Dodge, R
    Smith, R
    Szatrowski, T
    Schiffer, C
    [J]. BLOOD, 1997, 90 (10) : 2256 - 2256
  • [9] A Randomised Assessment of Vosaroxin Monotherapy and Vosaroxin Combined with Low Dose Ara-C Versus Low Dose Ara-C in Older Patients with Acute Myeloid Leukaemia
    Dennis, Michael
    Russell, Nigel H.
    Panoskaltsis, Nicki
    Hemmaway, Claire Jane
    Milligan, Donald
    Clark, Richard E.
    Hills, Robert K.
    Burnett, Alan K.
    [J]. BLOOD, 2014, 124 (21)
  • [10] Combined action of PSC 833 (Valspodar), a novel MDR reversing agent, with mitoxantrone, etoposide and cytarabine in poor-prognosis acute myeloid leukemia
    G Visani
    D Milligan
    F Leoni
    J Chang
    S Kelsey
    R Marcus
    R Powles
    S Schey
    A Covelli
    A Isidori
    M Litchman
    PP Piccaluga
    H Mayer
    M Malagola
    C Pfister
    [J]. Leukemia, 2001, 15 : 764 - 771
12345